UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/500/0.1/17.12.25 | Market Closed - Börse Stuttgart 11:48:51 17/05/2024 pm IST | ||
| 7.46 EUR | -2.74% |
|
| Current month | -28.20% | ||
| 1 month | -30.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 7.46 | -2.74% |
| 16/24/16 | 7.67 | -0.90% |
| 15/24/15 | 7.74 | -7.42% |
| 14/24/14 | 8.36 | +1.09% |
| 13/24/13 | 8.27 | -3.50% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 11:48 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1H5B |
| ISIN | DE000HD1H5B2 |
| Date issued | 28/12/2023 |
| Strike | 500 $ |
| Maturity | 17/12/2025 (579 Days) |
| Parity | 10 : 1 |
| Emission price | 9.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.83 € |
|---|---|
| Lowest since issue | 7.43 € |
| Spread | 0.03 € |
| Spread % | 0.40% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant